Joining Hands for New TB Drug Are Pharmaceutical Bigwigs

Efforts to aid research on a new drug for tuberculosis have been stepped up by pharmaceutical companies and research institutions.

Efforts to aid research on a new drug for tuberculosis have been stepped up by pharmaceutical companies and research institutions. These are in association with the Bill and Melinda Gates Foundation. Tuberculosis is a disease that annually kills three lakh Indians.

"The partnership, TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA is to create a TB drug that cures patients in only one month," a statement from pharma firm Sanofi said Wednesday.

Tuberculosis - Spread - Symptoms - Diagnosis - Treatment - FAQs
Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lung. It may spread to other organs.

Seven pharmaceutical companies and four research institutions have teamed up with the Bill and Melinda Gates Foundation for the goal.

Under the current TB course of medication, the patient has to be on antibiotics for at least six months, during which 20-30 percent patients drop out before completion.

With financial aid from the Gates Foundation, partners officially launched the TBDA in April and have begun the first round of screening for new TB drug candidates.

Screening Tests for Tuberculosis
Tuberculin skin test and Interferon – Release Assays are tests used to screen for tuberculosis.

"TB drug discovery has reached a crossroads. Finding new and faster-acting TB drugs will take a new kind of partnership, connecting not only academia and industry, but drug company with drug company," a Sanofi statement quoted Carl Nathan, professor and chairman of the department of microbiology and immunology at Weill Cornell Medical College, as saying.

The TBDA aims to develop five new preclinical drug candidates with treatment-shortening potential within 5 years and proof-of-concept for a one-month three-drug regimen within 10 years.

Drug Resistance – Antibiotic or Antimicrobial Resistance
Drug resistance is often a problem in malaria, tuberculosis, HIV, sexually transmitted diseases and hospital acquired diseases. Judicious use of antibiotics can control the problem.

The participating pharmacy giants include Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck and Sanofi. The companies will share data with American research institutions like Infectious Disease Research Institute, National Institute of Allergy and Infectious Diseases and Weill Cornell Medical College.

"The TB Drug Accelerator establishes a new paradigm of cooperation in drug discovery. By working together on this, we can optimize our research and speed the development of one of the most pressing needs in global health," said Chris Viehbacher, chief executive officer of Sanofi.

Vitamin D may Be Helpful to Curb Tuberculosis
A study of 131 people found the vitamin helped to boost the ability of the body to

Source-IANS